The impact of statin therapy on the prognosis of hormone receptor-positive breast cancer: a systematic review and meta-analysis - Scorecard - MDSpire

The impact of statin therapy on the prognosis of hormone receptor-positive breast cancer: a systematic review and meta-analysis

  • By

  • Xiaowen Ma

  • Yiming Sun

  • Yaqin Qi

  • Hiajiang Qu

  • Feng Zhang

  • June 3, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating the Prognostic Effects of Statin Treatment in Patients with Hormone Receptor-Positive Breast Cancer: A Comprehensive Meta-Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsStatins may reduce endocrine therapy resistance and improve overall survival through pleiotropic effects, as supported by the meta-analysis.
Target Population
Care Setting

Key Highlights

  • highlight_1

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor recurrence and survival outcomes in patients receiving statin therapy.
      • Evaluate potential side effects of statin therapy in breast cancer patients, including liver function tests and muscle symptoms.

      Risks

        Patient & Prescribing Data

        Patients diagnosed with hormone receptor-positive breast cancer.

        Statins may improve outcomes by mitigating endocrine therapy resistance.

        Clinical Best Practices

        • follow_up

        Related Resources & Content

        Original Source(s)

        The impact of statin therapy on the prognosis of hormone receptor-positive breast cancer: a systematic review and meta-analysis

        • by Xiaowen Ma, Yiming Sun, Yaqin Qi, Hiajiang Qu, Feng Zhang

        • June 3, 2026

        Related Content

        Artificial intelligence improves risk stratification for breast cancer recurrence and mortality in women exposed to pesticides: a call for reassessment of stratification criteria

        Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

        The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago

        • May 25, 2026

        • 9 min
        Management of toxicities from antibody – drug conjugates in breast cancer